P2RX7 and cancer: APC mutations were recently correlated with a poor response to immunotherapy in CRC [81], and given the role of both receptors in the cancer immune response [8, 11], it is tempting to speculate that the upregulation of P2X7 and A2A in these patients could be partly responsible for this phenomenon.